Last reviewed · How we verify
Vonoprazan+amoxicillin 7 days
Vonoprazan inhibits gastric acid secretion while amoxicillin kills Helicobacter pylori bacteria, together eradicating H. pylori infection.
Vonoprazan inhibits gastric acid secretion while amoxicillin kills Helicobacter pylori bacteria, together eradicating H. pylori infection. Used for Helicobacter pylori infection eradication.
At a glance
| Generic name | Vonoprazan+amoxicillin 7 days |
|---|---|
| Sponsor | Xijing Hospital of Digestive Diseases |
| Drug class | Potassium-competitive acid blocker + beta-lactam antibiotic combination |
| Target | H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vonoprazan is a potassium-competitive acid blocker (P-CAB) that suppresses gastric acid production by inhibiting the H+/K+-ATPase pump, creating an environment hostile to acid-dependent pathogens and allowing amoxicillin to penetrate gastric tissue more effectively. Amoxicillin is a beta-lactam antibiotic that disrupts bacterial cell wall synthesis. This combination is a standard triple-therapy regimen for H. pylori eradication.
Approved indications
- Helicobacter pylori infection eradication
Common side effects
- Diarrhea
- Nausea
- Abdominal discomfort
- Headache
- Rash (amoxicillin-related)
Key clinical trials
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- 7-day High-Dose Vonoprazan-amoxicillin Dual Therapy Versus 14-day Vonoprazan-amoxicillin Dual Therapy for H. Pylori (NA)
- Efficacy and Safety of 7-day Triple Therapy Containing Amoxicillin and Tetracycline Versus 14-day Dual Therapy for Helicobacter Pylori Eradication
- 7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy (PHASE4)
- VA Dual Sequential Therapy (PHASE4)
- 7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication (PHASE3)
- Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication (PHASE4)
- Triple Versus Quadruple Therapy for the Eradication of Helicobacter Pylori (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vonoprazan+amoxicillin 7 days CI brief — competitive landscape report
- Vonoprazan+amoxicillin 7 days updates RSS · CI watch RSS
- Xijing Hospital of Digestive Diseases portfolio CI